CTOs on the Move

Vera Therapeutics

www.veratx.com

 
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veratx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.770.0077

Executives

Name Title Contact Details
Scott Rossi
Head of Cybersecurity Profile

Funding

Vera Therapeutics raised $80M on 01/19/2021

Similar Companies

Graceway Pharmaceuticals

Graceway Pharmaceuticals is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hysitron

Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novo Nordisk

Headquartered in Denmark, Novo Nordisk has more than 5,000 employees in the United States – representing 16% of the total workforce. From our insulin product manufacturing facility in Clayton, , North Carolina, to our Research and Development Center in Seattle, Washington we bring value to communities across the country in a variety of ways.   Our newly constructed LEED-certified building in Plainsboro, New Jersey, is modeled on principles of functionality, innovation, openness, quality, and aesthetics-offering a space that promotes collaboration and creativity.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.